血漿分画製剤の世界市場:アルブミン製剤、免疫グロブリン製剤、第VIII因子、プロテアーゼ阻害薬

◆英語タイトル:Plasma Fractionation Market by Product (Albumin, Immunoglobulin, Factor VIII, Protease Inhibitors), Application (Neurology, Hematology, Rheumatology, Immunology), End User (Hospitals, Clinical Research Laboratories) - Global Forecast to 2021
◆商品コード:PH-4477
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2016年8月4日
◆ページ数:222
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥627,150見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥738,150見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥904,650見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、血漿分画製剤の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、市場環境分析、製品別分析、用途別分析、需要先別分析、地域別分析、血漿分画製剤の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

The global plasma fractionation market is projected to reach USD 26.07 Billion by 2021 from USD 18.84 Billion in 2016, at a CAGR of 6.7% from 2016 to 2021. The market is expected to witness significant growth in the coming years due to the rising demand for plasma derived products for the treatment of rare diseases.
Factors such as growing aging population, rising incidences of bleeding and immune disorders, and growing use of immunoglobulin and alpha-1-antitrypsin are the primary growth drivers for the global plasma fractionation market. The high cost of plasma products, adverse reactions associated with use of products, and limited reimbursement policies can hinder the growth of this market. Moreover, the increasing usage of recombinant coagulation factors as an alternative to plasma-derived coagulation factors is further hampering the growth of this market to a certain extent. Emerging markets such as China and India offer significant opportunities for the growth of market. Pricing pressure faced by the prominent market players is the major market challenge for this industry.

The report analyzes the plasma fractionation services market by products, applications, end users, and regions. On the basis of products, the global market is further segmented into albumin, immunoglobulin, coagulation factor concentrates, protease inhibitors, and other plasma fractionation products. In 2015, the immunoglobulin segment accounted for the largest share of the global market. The large share of this segment can primarily be attributed to rising incidences of neurological and immunological diseases, growing use of Intravenous immunoglobulin (IVIg) in various therapeutic areas, and rising adoption of subcutaneous immunoglobulin (SCIg). Based on application types, the market is segmented into neurology, immunology, haematology, pulmonology, haemato-oncology, rheumatology, critical care, and others. Based on end users, the market is segmented into hospitals and clinics, clinical research laboratories, and academic institutes. The hospitals and clinics segment accounted for the largest share of the global market in 2015. The increasing use of plasma products for labelled and off-labelled use for the treatment of various diseases in hospitals and clinics is the key factor for the growth of this market. In addition, the improvement of healthcare infrastructure in hospitals and clinics in emerging countries is expected to support the growth of the end-user segment.

In 2015, North America dominated the plasma fractionation market followed by Europe, Asia-pacific, and Rest of the World. Increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for diagnosed patients are factors driving the growth of this market. On the other hand, the Asia-Pacific (APAC) region is expected to witness the highest growth rate during the forecast period. This can be mainly attributed to rapid growth in the aging population, increasing use of albumin and immunoglobulin, and increasing number of hemophilic patients.

The global plasma fractionation market includes high-capacity fractionators, which provide plasma products across the globe and small to medium fractionators that cater to the demands of domestic markets. The market was dominated by five major players in 2015, together accounting for a share of around 65- 70%. On the other hand, there are several smaller players in the market which are based across developing countries, such as China, Singapore, Brazil, and Korea.

Some of the major players in this market are CSL Ltd. (Australia), Baxalta Incorporated (U.S.), Grifols S.A. (Spain), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).

【レポートの目次】

1 Introduction (Page No. – 15)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 18)
2.1 Research Approach
2.1.1 Secondary Sources
2.1.2 Key Data From Secondary Sources
2.1.3 Primary Sources
2.1.4 Key Data From Primary Sources
2.1.5 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation

3 Executive Summary (Page No. – 26)

4 Premium Insights (Page No. – 32)
4.1 Market Overview
4.2 Asia-Pacific Plasma Fractionation Market
4.3 Plasma Fractionation Market: Geographic Growth Opportunities
4.4 Plasma Fractionation Market: Geographic Mix
4.5 Plasma Fractionation Market: Developing vs Developed Countries

5 Market Overview (Page No. – 37)
5.1 Introduction
5.2 Market Dynamics
5.3 Key Market Drivers
5.3.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
5.3.2 Rise in the Aging Population Across the Globe
5.3.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1 Antitrypsin
5.3.4 Increase in Plasma Collection
5.4 Key Market Restraints
5.4.1 High Cost and Limited Reimbursements
5.4.2 Stringent Government Regulations
5.4.3 Emergence of Recombinant Alternatives
5.5 Key Market Opportunities
5.5.1 Increasing Number of Hemophilic Patients
5.6 Key Challenges
5.6.1 Pricing Pressure Faced By Prominent Players in the Market

6 Industry Insights (Page No. – 47)
6.1 Introduction
6.2 Key Industry Trends
6.2.1 Focus on Increasing Fractionation CAPACities and Geographical Expansions
6.2.2 New Indications for Plasma Products
6.2.3 Rising Adoption of SCIG
6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
6.2.5 Growing Plasma Products Market in China
6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Development of Recombinant Factors
6.3 Porter’s Five Forces Analysis
6.3.1 Threat of New Entrants
6.3.2 Threat of Substitutes
6.3.3 Bargaining Power of Suppliers
6.3.4 Bargaining Power of Buyers
6.3.5 Intensity of Competitive Rivalry

7 Global Plasma Fractionation Market, By Product (Page No. – 57)
7.1 Introduction
7.2 Fractionation Process
7.3 Immunoglobulin
7.3.1 Intravenous Immunoglobulin
7.3.2 Subcutaneous Immunoglobulin
7.3.3 Other Immunoglobulins
7.4 Coagulation Factor Concentrates
7.4.1 Factor VIII
7.4.2 Factor IX
7.4.3 Factor XIII
7.4.4 Prothrombin Complex Concentrates
7.4.5 Von Willebrand Factor (VWF)
7.4.6 Fibrinogen Concentrates
7.5 Albumin
7.6 Protease Inhibitors
7.7 Other Plasma Products

8 Global Plasma Fractionation Market, By Application (Page No. – 77)
8.1 Introduction
8.2 Neurology
8.3 Immunology
8.4 Hematology
8.5 Critical Care
8.6 Pulmonology
8.7 Hemato-Oncology
8.8 Rheumatology
8.9 Other Applications

9 Global Plasma Fractionation Market, By End User (Page No. – 94)
9.1 Introduction
9.2 Hospitals and Clinics
9.3 Clinical Research Laboratories
9.4 Academic Institutes

10 Global Plasma Fractionation Market, By Region (Page No. – 99)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 Italy
10.3.4 Spain
10.3.5 U.K.
10.3.6 Rest of Europe (RoE)
10.4 Asia-Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia-Pacific (Ro-APAC)
10.5 Rest of the World (RoW)
10.5.1 Latin America
10.5.2 Middle East and Africa

11 Competitive Landscape (Page No. – 168)
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Expansions
11.3.2 Agreements, Collaborations, and Partnerships
11.3.3 New Product Launches
11.3.4 Acquisitions

12 Company Profiles (Page No. – 176)
12.1 Introduction
12.2 CSL Ltd.
12.2.1 Business Overview
12.2.2 Products Offered
12.2.3 Recent Developments
12.2.4 MnM View
12.3 Grifols S.A.
12.3.1 Business Overview
12.3.2 Products Offered
12.3.3 Recent Developments
12.3.4 MnM View
12.4 Baxalta Incorporated
12.4.1 Business Overview
12.4.2 Products Offered
12.4.3 Recent Developments
12.4.4 MnM View
12.5 Octapharma AG
12.5.1 Business Overview
12.5.2 Products Offered
12.5.3 Recent Developments
12.5.4 MnM View
12.6 Kedrion S.P.A
12.6.1 Business Overview
12.6.2 Products Offered
12.6.3 Recent Developments
12.6.4 MnM View
12.7 China Biologic Products, Inc.
12.7.1 Business Overview
12.7.2 Products Offered
12.7.3 Recent Developments
12.8 Biotest AG
12.8.1 Business Overview
12.8.2 Products Offered
12.8.3 Recent Developments
12.9 LFB S.A.
12.9.1 Business Overview
12.9.2 Products Offered
12.9.3 Recent Developments
12.10 Bio Product Laboratory Ltd. (BPL)
12.10.1 Business Overview
12.10.2 Products Offered
12.10.3 Recent Developments
12.11 Sanquin
12.11.1 Business Overview
12.11.2 Products Offered

13 Appendix (Page No. – 197)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Other Developments
13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.5 Available Customizations
13.6 Introducing RT: Real-Time Market Intelligence
13.7 Related Reports

List of Tables (157 Tables)

Table 1 On-Label and Off-Label Indications of IVIG
Table 2 Growing Use of Immunoglobulins in Various Therapeutic Areas are Driving Market Growth
Table 3 High Cost and Limited Reimbursements are Restraining Market Growth
Table 4 Increasing Number of Hemophilic Patients Provide Significant Growth Opportunities
Table 5 Pricing Pressure Faced By Prominent Players in the Market is A Major Market Challenge
Table 6 Fractionation CAPACity Expansion By Major Players
Table 7 Per Capita Consumption of IVIG and Albumin, By Country (2012)
Table 8 Major Local Players in China
Table 9 Regional Impact Analysis of Recombinant Factors on Plasma-Derived Products
Table 10 Global Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 11 Global Market Size, By Country/Region, 2014–2021 (USD Million)
Table 12 Plasma Fractionation Process Flow
Table 13 Global Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 14 Global Immunoglobulin Market Size, By Country/Region, 2014–2021 (USD Million)
Table 15 Global IVIG Market Size, By Country/Region, 2014–2021 (USD Million)
Table 16 Global SCIG Market Size, By Country/Region, 2014–2021 (USD Million)
Table 17 Global Other Immunoglobulins Market Size, By Country/Region, 2014–2021 (USD Million)
Table 18 Global Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 19 Global Coagulation Factor Concentrates Market Size, By Country/Region, 2014–2021(USD Million)
Table 20 Mean Per Capita Usage of Factor VIII (2014)
Table 21 Global Factor VIII Market Size, By Country/Region, 2014–2021 (USD Million)
Table 22 Mean Per Capita Usage of Factor IX (2014)
Table 23 Global Factor IX Market Size, By Country/Region, 2014–2021 (USD Million)
Table 24 Global Factor XIII Market Size, By Country/Region, 2014–2021 (USD Million)
Table 25 Global Pcc Market Size, By Country/Region, 2014–2021 (USD Million)
Table 26 Global VWF Market Size, By Country/Region, 2014–2021 (USD Million)
Table 27 Fibrinogen Concentrates Market Size, By Country/Region, 2014–2021 (USD Million)
Table 28 Global Albumin Market Size, By Country/Region, 2014–2021 (USD Million)
Table 29 Global Protease Inhibitors Market Size, By Country/Region, 2014–2021 (USD Million)
Table 30 Global Other Plasma Products Market Size, By Country/Region, 2014–2021 (USD Million)
Table 31 Plasma Fractionation Market Size, By Application, 2014-2021 (USD Million)
Table 32 Plasma Fractionation Market Size for Neurology Applications, By Country/Region, 2014-2021 (USD Million)
Table 33 Market Size for Immunology, By Country/Region, 2014-2021 (USD Million)
Table 34 Global Number of Hemophilic Patients (2012-2014)
Table 35 Plasma Fractionation Market Size for Hematology, By Country/Region, 2014-2021 (USD Million)
Table 36 Market Size for Critical Care, By Country/Region, 2014-2021 (USD Million)
Table 37 Plasma Fractionation Market Size for Pulmonology Applications, By Country/Region, 2014-2021 (USD Million)
Table 38 Market Size for Hemato-Oncology, By Country/Region, 2014-2021 (USD Million)
Table 39 Plasma Fractionation Market Size for Rheumatology, By Country/Region, 2014-2021 (USD Million)
Table 40 Plasma Fractionation Market Size for Other Applications, By Country/Region, 2014-2021 (USD Million)
Table 41 Market Size, By End User, 2014–2021 (USD Million)
Table 42 Global Market Size for Hospitals and Clinics, By Country, 2014–2021 (USD Million)
Table 43 Clinical Studies on Albumin & Immunoglobulin
Table 44 Global Market Size for Clinical Research Laboratories, By Country, 2014–2021 (USD Million)
Table 45 Global Market Size for Academic Institutes, By Country, 2014–2021 (USD Million)
Table 46 Global Market Size, By Region, 2014–2021 (USD Million)
Table 47 North America: Total Hemophilia Patients, 2013 vs 2014
Table 48 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 49 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 50 North America: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 51 North America: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 52 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 53 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 54 Distribution of Primary Immunodeficiency Patients in the U.S., 2014
Table 55 People With Hemophilia A & Hemophilila B in U.S., 2013-2014
Table 56 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 57 U.S.: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 58 U.S.: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 59 U.S.: Market Size, By Application, 2014–2021 (USD Million)
Table 60 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 61 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 62 Canada: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 63 Canada: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 64 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 65 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 66 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 67 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 68 Europe: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 69 Europe: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 70 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 71 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 72 Germany: Market Size, By Product, 2014–2021 (USD Million)
Table 73 Germany: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 74 Germany: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 75 Germany: Market Size, By Application, 2014–2021 (USD Million)
Table 76 Germany: Market Size, By End User, 2014–2021 (USD Million)
Table 77 Number of People With Bleeding Disorders in France : 2012-2014
Table 78 France: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 79 France: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 80 France: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 81 France: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 82 France: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 83 Production of Plasma Products in Italy: 2013
Table 84 Italy: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 85 Italy: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 86 Italy: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 87 Italy: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 88 Italy: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 89 Spain: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 90 Spain: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 91 Spain: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 92 Spain: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 93 Spain: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 94 Usage of Immunoglobulins, 2014
Table 95 Estimated No. of Hemophilia A & B Patients in the U.K.: 2012-2014
Table 96 U.K.: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 97 U.K.: Coagulation Factor Concentrates Market Size, By Type, 2014–2019 (USD Million)
Table 98 U.K.: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 99 U.K.: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 100 Total Hemophilia Patients in the RoE: 2012-2014
Table 101 Access to Treatments for Bleeding Disorders in the RoE
Table 102 RoE: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 103 RoE: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 104 RoE: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 105 RoE: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 106 RoE: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 107 Asia-Pacific: Plasma Fractionation Market Size, By Country, 2014–2021 (USD Million)
Table 108 Asia-Pacific: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 109 Asia-Pacific: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 110 Asia-Pacific: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 111 Asia-Pacific: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 112 Asia-Pacific: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 113 China: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 114 China: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 115 China: Coagulation Factor Concentrates Market Size, By Type, 2012–2021 (USD Million)
Table 116 China: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 117 China: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 118 Japan: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 119 Japan: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 120 Japan: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 121 Japan: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 122 Japan: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 123 Number of Patients With Bleeding Disorders: 2012-2014
Table 124 India: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 125 India: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 126 India: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 127 India: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 128 India: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 129 Rest of Asia-Pacific: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 130 Rest of Asia-Pacific: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 131 Rest of Asia-Pacific: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 132 Rest of Asia-Pacific: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 133 Rest of Asia-Pacific: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 134 RoW: Plasma Fractionation Market Size, By Region, 2014–2021 (USD Million)
Table 135 RoW: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 136 RoW: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 137 RoW: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 138 RoW: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 139 RoW: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 140 Estimated Hemophilia Patients in Brazil: 2012-2014
Table 141 Latin America: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 142 Latin America: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 143 Latin America: Coagulation Factor Concentrates Market Size, By Type, 2014–2012 (USD Million)
Table 144 Latin America: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 145 Latin America: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 146 Estimated Hemophilia Patients in the Middle East and Africa: 2012-2014
Table 147 Per Capita Consumption of Factor IX and VIII (Iu/Total Population : 2012 & 2014
Table 148 Middle East and Africa: Plasma Fractionation Market Size, By Product, 2014–2021 (USD Million)
Table 149 Middle East and Africa: Immunoglobulin Market Size, By Type, 2014–2021 (USD Million)
Table 150 Middle East and Africa: Coagulation Factor Concentrates Market Size, By Type, 2014–2021 (USD Million)
Table 151 Middle East and Africa: Plasma Fractionation Market Size, By Application, 2014–2021 (USD Million)
Table 152 Middle East and Africa: Plasma Fractionation Market Size, By End User, 2014–2021 (USD Million)
Table 153 Growth Strategy Matrix, 2013–2016
Table 154 Recent Developments (2013–2016)
Table 155 Agreements, Partnerships, and Collaborations (2013–2016)
Table 156 New Product Launches (2013-2016)
Table 157 Acquisitions (2013-2016)


List of Figures (52 Figures)

Figure 1 Research Design
Figure 2 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 Immunoglobulin to Dominate the Global Plasma Fractionation Market, By Product, During 2016 to 2021
Figure 7 Neurology Segment to Register the Highest Growth During the Forecast Period
Figure 8 Global Plasma Fractionation Market, By End User, 2016 vs 2021 (USD Million)
Figure 9 Geographic Snapshot: Global Plasma Fractionation Market in 2015
Figure 10 Growing Use of Immunoglobulins Will Drive Market Growth During 2016–2021
Figure 11 Hospitals and Clinics Accounted for the Largest Share in the Asia-Pacific Plasma Fractionation Market, 2015
Figure 12 The U.S. Commanded the Major Share of the Global Plasma Fractionation Market in 2015
Figure 13 North America to Dominate the Plasma Fractionation Market in 2016
Figure 14 Developing Markets to Register Highest Growth in the Forecast Period (2016-2021)
Figure 15 Plasma Fractionation Market : Drivers, Restraints, Opportunities, and Challenges
Figure 16 Copd and Asthma Prevalence, By Country
Figure 17 Global Deaths From Respiratory Diseases, 2000 vs 2012 (Thousand Individuals)
Figure 18 Plasma Collection in Europe (Gross Million Liters): 2005–2013
Figure 19 Source Plasma Collection in the U.S., 2005–2013
Figure 20 Number of Hemophilia A & Hemophilia B Patients Worldwide: 2012–2014
Figure 21 Increasing Consolidation and Rising Adoption of SCIG are the Leading Industry Trends
Figure 22 Plasma Fractionation Market in China vs Developed Countries, 2016 vs 2021
Figure 23 Albumin Market Share in China, By Key Player, 2015
Figure 24 Porter’s Five Forces Analysis
Figure 25 Estimated Life-Time Risk of Alzheimer’s Disease, By Age & Sex
Figure 26 Number of People With Different Bleeding Disorders, 2014
Figure 27 Neurology Segment Will Continue to Dominate the Global Plasma Fractionation Market From 2016 to 2021
Figure 28 Number of Dalys for Neurological Disorders as Percentage of Global Dalys (2005, 2015, & 2030)
Figure 29 Trend Analysis of Primary Immodeficiency Patients Followed, Referred, Identified, and Treated (2004-2013)
Figure 30 Number of Hemophilia Patients in Major Countries, 2014
Figure 31 Estimated Incidence and Mortality Rate of Blood Cancer Types in Developed and Developing Countries, By Sex, 2012
Figure 32 Geographic Snapshot (2016) – Rapid Growth Markets are Emerging as New Hotspots
Figure 33 North American Plasma Fractionation Market Snapshot
Figure 34 Number of Plasma Donations in the U.S., 2003-2014
Figure 35 Hemophilia A & B Patients in Germany, 2008 vs 2014
Figure 36 Mean Per Capita Consumption of Factor VIII & Factor IX -2012&2014
Figure 37 APAC Plasma Fractionation Market Snapshot
Figure 38 Companies Primarily Adopted the Strategy of Expansions From 2013 to 2016
Figure 39 Global Plasma Fractionation Market Share Analysis, By Key Player, 2015
Figure 40 Battle for Market Share: Expansions Was the Key Strategy
Figure 41 Geographic Revenue Mix of the Major Players (2015)
Figure 42 Company Snapshot: CSL Ltd.
Figure 43 Company Snapshot: Grifols S.A.
Figure 44 Company Snapshot: Baxalta Incorporated
Figure 45 Company Snapshot: Octapharma AG
Figure 46 Company Snapshot: Kedrion S.P.A
Figure 47 Company Snapshot: China Biologic Products, Inc.
Figure 48 Company Snapshot: Biotest AG
Figure 49 Company Snapshot: LFB S.A.
Figure 50 Company Snapshot: Sanquin
Figure 51 Marketsandmarkets Knowledge Store Snapshot
Figure 52 Marketsandmarkets Knowledge Store: Healthcare Industry Snapshot

【レポートのキーワード】

血漿分画、血漿分画製剤、アルブミン製剤、免疫グロブリン製剤、第VIII因子、原料血漿、プロテアーゼ阻害剤、血液凝固因子、医療、治療、医薬品、血漿分画製剤用途

★調査レポート[血漿分画製剤の世界市場:アルブミン製剤、免疫グロブリン製剤、第VIII因子、プロテアーゼ阻害薬]販売に関する免責事項
★調査レポート[血漿分画製剤の世界市場:アルブミン製剤、免疫グロブリン製剤、第VIII因子、プロテアーゼ阻害薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆